Navigation Links
Endocrine Society calls for large-scale studies to evaluate testosterone therapy risks
Date:2/7/2014

Chevy Chase, MDAccording to a statement issued today by the Endocrine Society, the risks and benefits of testosterone therapy for older men with declining levels of the hormone need to be fully evaluated.

The statement comes in response to recent studies that have raised concerns about the safety of testosterone therapy in older men with a history of heart disease. Two retrospective analyses and one randomized trial supported by the Veterans Health Care System, and the National Institutes of Health found a higher rate of cardiovascular events in men who received testosterone and had preexisting heart problems. The U.S. Food and Drug Administration has announced it plans to evaluate the safety of testosterone therapy.

Testosterone is approved for the treatment of hypogonadism due to known diseases of the testes, pituitary and hypothalamus. Although the use of testosterone therapy is increasing, the treatment has not been approved for the treatment of age-related symptoms or the age-related decline of testosterone levels.

Important safety data are expected from the NIA's ongoing randomized trial examining testosterone in about 800 older men with unequivocally low testosterone levels and accompanying symptoms, including sexual and physical dysfunction. The trial's structure and careful monitoring of cardiovascular events will help provide important safety information.

The Society calls for the development of more large-scale randomized controlled trials to determine the true risks and benefits of testosterone therapy in older men.

In the statement, the Society recommends that middle-aged and older men who are considering testosterone supplementation for age-related declines should be informed of the potential cardiovascular risks. The Society also believes that it may be prudent not to administer testosterone therapy to men who have had a cardiovascular event (such as myocardial infarction, stroke or acute coronary syndrome) in the preceding six months.

In cases where men are being treated for hypogonadism as a result of known diseases of the testes, pituitary and hypothalamus, however, patients should consult their health care providers before making any changes to their medication regimen. The Society believes testosterone is generally safe and beneficial when used to treat young, hypogonadal men with these conditions. The Society's Clinical Practice Guideline on testosterone therapy in this population is available at http://www.endocrine.org/~/media/endosociety/Files/Publications/Clinical%20Practice%20Guidelines/FINAL-Androgens-in-Men-Standalone.pdf.


'/>"/>

Contact: Jenni Glenn Gingery
jgingery@endocrine.org
301-941-0240
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma
2. Simpler lifestyle found to reduce exposure to endocrine-disrupting chemicals
3. Imaging agents predict breast cancer response to endocrine therapy
4. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
5. Researchers craft tool to minimize threat of endocrine disruptors in new chemicals
6. UCLA study finds endocrine disorder is most common cause of elevated calcium levels
7. Endocrine Society announces 2014 Laureate Award winners
8. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
9. New American Chemical Society video: Behind the scenes tour of an electronic nose lab
10. The Gerontological Society of America Selects 2012 Fellows
11. Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... 2017 , ... CareAcademy, a provider of specialized online training ... in seed funding to further expand its course portfolio and increase its market ... the company’s primary investors. , Founded in 2016, CareAcademy currently serves ...
(Date:8/17/2017)... ... August 17, 2017 , ... Pot Valet is a leading provider of ... city in the state, and soon, every state in the country, the company offers ... a cannabis dispensary altogether. , According to Pot Valet, all California patients ...
(Date:8/17/2017)... ... ... Media, the industry leader in digital marketing for medical practices, has been recognized as one ... the Inc. 5000 for the second time in two years. Shawn Miele, Chief Executive Officer ... for the second year in a row. It’s extremely difficult to make this list once. ...
(Date:8/17/2017)... ... August 17, 2017 , ... Finalists in the 2017 ... announced today. The awards recognize the world’s best employers and the human resources ... drive great places to work. , A diverse group of organizations and individuals ...
(Date:8/17/2017)... WA and Lighthouse Point, FL (PRWEB) , ... ... ... healthcare technology firm and Cancer Center Business Development Group, a Florida-based oncology business ... examined patient care data to quantify the dollar amount of attributable savings from ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... announced today that its fully owned USA -operating ... City Office in Yonkers, New York to ... 2 ) homecare therapy. This new East Coast location has also ... the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New York ...
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), ... in Lakewood, Colorado . The reputable clinic ... Lipkin , PT, DPT with his staff of four clinicians. ... of Pittsburgh and brings over 10 years of experience with ... Belmar PT marks the 10th PRN clinic in and ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
Breaking Medicine Technology: